Can FDA Learn From Industry’s Risk/Benefit Decisions?
Executive Summary
FDA is seeking insight into the pharmaceutical industry's pipeline management decisions as it works to improve its own risk/benefit analyses
You may also be interested in...
PDUFA Pilots: Risk/Benefit Plan Takes Off As “Continuous” Applications Stop
FDA's proposals for renewal of the Prescription Drug User Fee Act will continue the program's function as an incubator of new regulatory approaches by the agency
PDUFA Pilots: Risk/Benefit Plan Takes Off As “Continuous” Applications Stop
FDA's proposals for renewal of the Prescription Drug User Fee Act will continue the program's function as an incubator of new regulatory approaches by the agency
Innovative Drug Development Demands Clearer Regulatory Pathways From FDA
Speeding development of innovative therapies requires FDA to more clearly define regulatory pathways for novel drugs, former Abbott Pharma President & COO Jeffrey Leiden said